Australia's largest stock trading and investment forum Australia's #1 stock forum

SYT

0.00%

0.1¢ syntonic limited

SYT General, page-1829

First 1829 Last

Share
Profile

Follow
Stuka

1,064 Posts.

4

15/07/17

12:29

Post #: 25884129
Share

Originally posted by Nighthawk10000 ↑

Acca, the so called business strategy you're talking about has never been communicated to investors; these are your assumptions. So using finite phrases like "GG wants this" and "doesn't want that" are erroneous and misleading. One thing that has been made clear to investors, by way of the investor presentation, is the product they have to offer (Freeway) and their competition in the space. Aquto is Syntonic's direct competition, they have a relatively complete solution and decent ability to execute, according to Syntonic. Saying that SYT has protected IP's is and therefore a better option for telcos is also silly, all the companies listed below have protected. The other thing that I find ridiculous is the whole " SYT don't need 100% of the market", as it stands SYT would be lucky to have cornered 5% of the market. So loosing big contracts like Telefonica that has a large market share (especially in Europe), is a substantial blow to the company's land grab.

The big picture here is; why did Telefonica choose Aquto over SYT? Is SYT's solution not up to scratch? Are SYT more focussed on OTT and the United States at this point in time?

View attachment 646299

Expand

Sorry can you substantiate where you got 5% from. After all yoy are the one calling people on unsubstantiated statements.

SYT Price at posting: 2.9¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability